View Older Stories View More Recent Stories

Feb 27, 2017 08:35AM Sanofi (SNY) and Regeneron (REGN) to Present New Data on Dupixent for Moderate-to-Severe Atopic Dermatitis
Feb 27, 2017 08:30AM Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 27, 2017 08:30AM Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 13, 2017 09:30AM Regeneron Announces Upcoming 2017 Investor Conference Presentations
Feb 9, 2017 09:24AM Pre-Open Movers 02/09: (OSUR) (ACOR) (PAYC) Higher; (TWTR) (OII) (QLYS) Lower (more...)
Feb 9, 2017 06:30AM Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
Feb 8, 2017 05:44PM Sanofi: Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
Feb 8, 2017 05:32PM Regeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN)
Feb 8, 2017 05:30PM Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
Feb 7, 2017 06:30AM Regeneron to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2017
Feb 1, 2017 02:15AM Health Canada Approves Sanofi & Regeneron "Kevzara (sarilumab)" Used To Treat Moderate To Severe Active Rheumatoid Arthritis In Adult Patients
Feb 1, 2017 01:01AM Sanofi and Regeneron Announce First Approval of Kevzara(TM) (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
Feb 1, 2017 01:00AM Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
Jan 31, 2017 07:00AM Tony Coles, M.D., Elected to Regeneron Board of Directors
Jan 24, 2017 12:01PM Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
Jan 24, 2017 12:00PM Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists
Jan 5, 2017 08:00PM Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Jan 4, 2017 07:00AM Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Dec 22, 2016 02:05PM Geisinger and Regeneron (REGN) DiscovEHR Collaboration Higlighted in Science Publication
Dec 22, 2016 02:00PM Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Dec 22, 2016 02:00PM Science Publication Highlights the Precision Medicine Approach of Geisinger Health System and the Regeneron Genetics Center
Dec 22, 2016 02:00PM Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System
Dec 22, 2016 09:30AM Regeneron Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
Dec 8, 2016 06:21AM Regeneron (REGN), Sanofi (SNY) Announce EMA Acceptance of Dupixent Marketing App
Dec 8, 2016 01:00AM Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
Dec 8, 2016 01:00AM Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
Nov 21, 2016 08:30AM Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year
Nov 17, 2016 02:01AM Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis
Nov 17, 2016 02:00AM Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Nov 16, 2016 08:01AM Regeneron (REGN), Sanofi (SNY) Announce Presentation of Strong Sarilumab Monotherapy Phase 3 Data vs. Humira
Nov 16, 2016 08:00AM Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Nov 16, 2016 08:00AM Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Nov 11, 2016 09:02AM Regeneron (REGN), Sanofi (SNY) Present Praluent Phase 3 Data in Lowering LDL-C
Nov 11, 2016 09:00AM Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Nov 4, 2016 06:30AM Regeneron Reports Third Quarter 2016 Financial and Operating Results
Oct 28, 2016 02:36PM Regeneron (REGN), Sanofi (SNY) Receive FDA Complete Response Letter for Sarilumab BLA as RA Treatment
Oct 28, 2016 02:35PM Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Oct 27, 2016 02:05PM Science Magazine Once Again Names Regeneron the Best Company to Work For
Oct 21, 2016 09:30AM Regeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference
Oct 17, 2016 07:05AM Teva Pharma (TEVA), Regeneron (REGN) Announce FDA Clinical Hold Placed on Fasinumab Phase 2b
Oct 17, 2016 07:00AM Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Oct 17, 2016 07:00AM Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Oct 7, 2016 09:30AM Regeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016
Oct 5, 2016 08:30AM New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
Oct 5, 2016 08:30AM New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
Oct 3, 2016 06:32AM Regeneron (REGN), Sanofi (SNY) Announce Publication of Positive Dupixent Phase 3 Data as AD Treatment
Oct 1, 2016 02:00AM Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Sep 30, 2016 07:01AM Regeneron (REGN) Announces EYLEA Phase 2 CAPELLA Missed Primary Endpoint in Neovascular Age-Related Macular Degeneration
Sep 30, 2016 07:00AM Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
Sep 26, 2016 06:18AM Regeneron (REGN), Sanofi (SNY) Announce Dupilumab BLA Accepted for Priority Review by FDA
View More Recent Stories View Older Stories